Scientific Reports (Apr 2024)

Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes

  • Yoscelina Estrella Martínez-López,
  • Daniel Neri-Rosario,
  • Diego Armando Esquivel-Hernández,
  • Cristian Padron-Manrique,
  • Aarón Vázquez-Jiménez,
  • Jean Paul Sánchez-Castañeda,
  • David Girón-Villalobos,
  • Cristian Mendoza-Ortíz,
  • María de Lourdes Reyes-Escogido,
  • Maria Lola Evia-Viscarra,
  • Alberto Aguilar-Garcia,
  • Osbaldo Resendis-Antonio,
  • Rodolfo Guardado-Mendoza

DOI
https://doi.org/10.1038/s41598-024-60081-y
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Lifestyle modifications, metformin, and linagliptin reduce the incidence of type 2 diabetes (T2D) in people with prediabetes. The gut microbiota (GM) may enhance such interventions' efficacy. We determined the effect of linagliptin/metformin (LM) vs metformin (M) on GM composition and its relationship to insulin sensitivity (IS) and pancreatic β-cell function (Pβf) in patients with prediabetes. A cross-sectional study was conducted at different times: basal, six, and twelve months in 167 Mexican adults with prediabetes. These treatments increased the abundance of GM SCFA-producing bacteria M (Fusicatenibacter and Blautia) and LM (Roseburia, Bifidobacterium, and [Eubacterium] hallii group). We performed a mediation analysis with structural equation models (SEM). In conclusion, M and LM therapies improve insulin sensitivity and Pβf in prediabetics. GM is partially associated with these improvements since the SEM models suggest a weak association between specific bacterial genera and improvements in IS and Pβf.

Keywords